Peritoneal carcinoma

Summary

Peritoneal carcinoma (MONDO:0002113) is a cancer with 3 cohort genes (3 CIViC-evidence somatic drivers) and 287 clinical trials. Molecularly, BRCA1 Mutation OR BRCA2 Mutation confers sensitivity to Niraparib in Peritoneal Carcinoma (CIViC Level A); 1 further subtype–drug associations are mapped below. Top therapeutic interventions include carboplatin, topotecan, and cabozantinib.

At a glance

• Classification: Cancer
• Cohort genes: 3
• Clinical trials: 287
• Precision-medicine evidence (CIViC): 2 subtype–drug associations

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	peritoneal carcinoma
Mondo ID	MONDO:0002113
DOID	DOID:1791
SNOMED CT	447781009
UMLS	C3163804
MedGen	756216
Anatomy (UBERON)	UBERON:0002358
Is cancer (heuristic)	yes

Also known as: carcinoma of peritoneum · peritoneum carcinoma · primary peritoneal carcinoma

Data availability: 24 cell lines.

Disease family

An umbrella term covering 3 Mondo subtypes.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › peritoneum cancer › peritoneal carcinoma

Related subtypes (5): round ligament malignant neoplasm, malignant peritoneal solitary fibrous tumor, malignant peritoneal mesothelioma, malignant peritoneal germ cell tumor, peritoneal carcinomatosis

Subtypes (3): peritoneal serous adenocarcinoma, primary peritoneal carcinoma, pseudomyxoma peritonei

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 25 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Somatic driver evidence (intOGen + CIViC, cohort fanout)

Gene	intOGen role	Cancer types	CIViC
BRCA1	LoF	BLCA,BRCA,MEL,OVT	CIViC #6
BRCA2	LoF	BLCA,BRCA,CESC,CHOL,HCC,HNSC,LUSC,MBL,OVT,PAAD,PRAD,PROSTATE,RCC,VULVA	CIViC #7
ERBB2	Act	BLCA,BRCA,CESC,CHOL,COADREAD,EGC,ESCA,ESCC,LMS,LUAD,NSCLC,OVT,PRCC,READ,STAD,UCEC	CIViC #20

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
BRCA1	Orphanet:1331	Familial prostate cancer
BRCA1	Orphanet:1333	Familial pancreatic carcinoma
BRCA1	Orphanet:145	Hereditary breast and/or ovarian cancer syndrome
BRCA1	Orphanet:168829	Primary peritoneal carcinoma
BRCA1	Orphanet:227535	Hereditary breast cancer
BRCA1	Orphanet:667662	Breast implant-associated anaplastic large cell lymphoma
BRCA1	Orphanet:694963	Inflammatory breast cancer
BRCA1	Orphanet:70567	Cholangiocarcinoma
BRCA1	Orphanet:84	Fanconi anemia
BRCA2	Orphanet:1331	Familial prostate cancer
BRCA2	Orphanet:1333	Familial pancreatic carcinoma
BRCA2	Orphanet:145	Hereditary breast and/or ovarian cancer syndrome
BRCA2	Orphanet:178	Chordoma
BRCA2	Orphanet:227535	Hereditary breast cancer
BRCA2	Orphanet:319462	Inherited cancer-predisposing syndrome due to biallelic BRCA2 mutations
BRCA2	Orphanet:440437	Familial colorectal cancer Type X
BRCA2	Orphanet:654	Nephroblastoma
BRCA2	Orphanet:667662	Breast implant-associated anaplastic large cell lymphoma
BRCA2	Orphanet:694963	Inflammatory breast cancer
BRCA2	Orphanet:70567	Cholangiocarcinoma
BRCA2	Orphanet:84	Fanconi anemia
ERBB2	Orphanet:213726	Serous carcinoma of the corpus uteri
ERBB2	Orphanet:2800	Extramammary Paget disease
ERBB2	Orphanet:388	Hirschsprung disease
ERBB2	Orphanet:99976	Adenocarcinoma of the oesophagus and oesophagogastric junction

Cohort genes → proteins

3 cohort genes, 3 distinct canonical proteins.

Evidence partition

Subset	Genes
civic_only	3

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
BRCA1	HGNC:1100	ENSG00000012048	P38398	Breast cancer type 1 susceptibility protein	civic_evidence
BRCA2	HGNC:1101	ENSG00000139618	P51587	Breast cancer type 2 susceptibility protein	civic_evidence
ERBB2	HGNC:3430	ENSG00000141736	P04626	Receptor tyrosine-protein kinase erbB-2	civic_evidence

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
BRCA1	Breast cancer type 1 susceptibility protein	E3 ubiquitin-protein ligase that specifically mediates the formation of ‘Lys-6’-linked polyubiquitin chains and plays a central role in DNA repair by facilitating cellular responses to DNA damage.
BRCA2	Breast cancer type 2 susceptibility protein	Involved in double-strand break repair and/or homologous recombination.
ERBB2	Receptor tyrosine-protein kinase erbB-2	Protein tyrosine kinase that is part of several cell surface receptor complexes, but that apparently needs a coreceptor for ligand binding.

Protein-family classification

Druggable: 1 · Difficult: 1 · Unknown: 1 · Druggable fraction: 0.33

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Kinase	1	9.2×	0.313
Transcription factor	1	2.8×	0.482
Other/Unknown	1	0.6×	0.914

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
BRCA1	Transcription factor	no	2.3.2.27	BRCT_dom, Znf_RING, BRCA1
BRCA2	Other/Unknown	no		BRCA2_repeat, NA-bd_OB-fold, BRCA2_OB_1
ERBB2	Kinase	yes	2.7.10.1	Rcpt_L-dom, Prot_kinase_dom, Ser-Thr/Tyr_kinase_cat_dom

Expression context

Cohort genes with no expression data: 0.

3 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	3
unknown	0

Top tissues across cohort

Tissue	Cohort genes
male germ line stem cell (sensu Vertebrata) in testis	2
ventricular zone	2
primordial germ cell in gonad	1
secondary oocyte	1
lower esophagus mucosa	1
right uterine tube	1
sural nerve	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
BRCA1	208	ubiquitous	marker	ventricular zone, male germ line stem cell (sensu Vertebrata) in testis, primordial germ cell in gonad
BRCA2	184	ubiquitous	marker	male germ line stem cell (sensu Vertebrata) in testis, secondary oocyte, ventricular zone
ERBB2	276	ubiquitous	marker	lower esophagus mucosa, right uterine tube, sural nerve

Protein interactions among cohort

Intra-cohort edges: 1.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
ERBB2	9,659
BRCA1	9,064
BRCA2	4,839

Intra-cohort edges

A	B	Sources
BRCA1	BRCA2	string_interaction

Structural data

PDB: 3 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
ERBB2	P04626	63
BRCA1	P38398	33
BRCA2	P51587	14

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 95. Enrichment computed across 3 evidence-associated genes (3 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 3 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Defective homologous recombination repair (HRR) due to PALB2 loss of function	2	634.4×	1e-04	BRCA1, BRCA2
Diseases of DNA Double-Strand Break Repair	2	543.8×	1e-04	BRCA1, BRCA2
Defective homologous recombination repair (HRR) due to BRCA2 loss of function	2	543.8×	1e-04	BRCA1, BRCA2
Resolution of D-Loop Structures	2	423.0×	2e-04	BRCA1, BRCA2
Diseases of DNA repair	2	380.7×	2e-04	BRCA1, BRCA2
Impaired BRCA2 binding to PALB2	2	304.5×	2e-04	BRCA1, BRCA2
Defective homologous recombination repair (HRR) due to BRCA1 loss of function	2	282.0×	2e-04	BRCA1, BRCA2
Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function	2	282.0×	2e-04	BRCA1, BRCA2
Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function	2	282.0×	2e-04	BRCA1, BRCA2
Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA)	2	262.5×	2e-04	BRCA1, BRCA2
Homologous DNA Pairing and Strand Exchange	2	253.8×	2e-04	BRCA1, BRCA2
Homology Directed Repair	2	205.8×	2e-04	BRCA1, BRCA2
HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA)	2	205.8×	2e-04	BRCA1, BRCA2
Impaired BRCA2 binding to RAD51	2	205.8×	2e-04	BRCA1, BRCA2
Resolution of D-loop Structures through Holliday Junction Intermediates	2	200.3×	2e-04	BRCA1, BRCA2
Meiosis	2	190.3×	2e-04	BRCA1, BRCA2
Presynaptic phase of homologous DNA pairing and strand exchange	2	181.3×	2e-04	BRCA1, BRCA2
DNA Double-Strand Break Repair	2	165.5×	3e-04	BRCA1, BRCA2
Reproduction	2	126.9×	4e-04	BRCA1, BRCA2
HDR through Homologous Recombination (HRR)	2	126.9×	4e-04	BRCA1, BRCA2
Meiotic recombination	2	86.5×	8e-04	BRCA1, BRCA2
DNA Repair	2	65.6×	0.001	BRCA1, BRCA2
Defective DNA double strand break response due to BRCA1 loss of function	1	1903.3×	0.002	BRCA1
Defective DNA double strand break response due to BARD1 loss of function	1	1903.3×	0.002	BRCA1
Impaired BRCA2 translocation to the nucleus	1	1268.9×	0.003	BRCA2
Impaired BRCA2 binding to SEM1 (DSS1)	1	1268.9×	0.003	BRCA2
PLCG1 events in ERBB2 signaling	1	951.7×	0.003	ERBB2
Drug-mediated inhibition of ERBB2 signaling	1	951.7×	0.003	ERBB2
Resistance of ERBB2 KD mutants to trastuzumab	1	951.7×	0.003	ERBB2
Resistance of ERBB2 KD mutants to sapitinib	1	951.7×	0.003	ERBB2

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 3 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
regulation of DNA damage checkpoint	2	749.0×	2e-04	BRCA1, BRCA2
cellular response to ionizing radiation	2	274.0×	9e-04	BRCA1, BRCA2
double-strand break repair	2	135.4×	0.002	BRCA1, BRCA2
double-strand break repair via homologous recombination	2	104.0×	0.003	BRCA1, BRCA2
mitotic recombination-dependent replication fork processing	1	2808.7×	0.007	BRCA2
immature T cell proliferation in thymus	1	1123.5×	0.010	ERBB2
negative regulation of mammary gland epithelial cell proliferation	1	1123.5×	0.010	BRCA2
cellular response to indole-3-methanol	1	1123.5×	0.010	BRCA1
negative regulation of immature T cell proliferation in thymus	1	936.2×	0.010	ERBB2
ERBB2-ERBB4 signaling pathway	1	936.2×	0.010	ERBB2
chordate embryonic development	1	936.2×	0.010	BRCA1
negative regulation of centriole replication	1	802.5×	0.010	BRCA1
establishment of protein localization to telomere	1	702.2×	0.010	BRCA2
DNA strand resection involved in replication fork processing	1	702.2×	0.010	BRCA1
regulation of microtubule-based process	1	624.1×	0.010	ERBB2
DNA damage tolerance	1	561.7×	0.010	BRCA1
response to UV-C	1	561.7×	0.010	BRCA2
ERBB2-ERBB3 signaling pathway	1	561.7×	0.010	ERBB2
ERBB2-EGFR signaling pathway	1	561.7×	0.010	ERBB2
telomere maintenance via recombination	1	510.7×	0.010	BRCA2
homologous recombination	1	468.1×	0.011	BRCA1
enzyme-linked receptor protein signaling pathway	1	432.1×	0.011	ERBB2
negative regulation of intracellular estrogen receptor signaling pathway	1	374.5×	0.011	BRCA1
Schwann cell development	1	351.1×	0.011	ERBB2
negative regulation of gene expression via chromosomal CpG island methylation	1	351.1×	0.011	BRCA1
inner cell mass cell proliferation	1	330.4×	0.011	BRCA2
protein K6-linked ubiquitination	1	330.4×	0.011	BRCA1
centrosome duplication	1	312.1×	0.011	BRCA2
random inactivation of X chromosome	1	312.1×	0.011	BRCA1
negative regulation of reactive oxygen species metabolic process	1	312.1×	0.011	BRCA1

Therapeutics

Drug target analysis

Approved (phase 4): 2 · Phase ≥3: 2 · Phased (≥1): 2 · Undrugged: 1

Druggability breadth: 2 of 3 evidence-associated genes (67%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

Symbol	Example approved molecule
BRCA1	RIBOFLAVIN
ERBB2	CLOTRIMAZOLE

Top cohort targets by molecule count

Symbol	Molecules	Max phase
ERBB2	83	4
BRCA1	12	4
BRCA2	0	0

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
RIBOFLAVIN	4	BRCA1
DAUNORUBICIN HYDROCHLORIDE	4	BRCA1
TOPOTECAN HYDROCHLORIDE	4	BRCA1
DAUNORUBICIN	4	BRCA1
DOXORUBICIN HYDROCHLORIDE	4	BRCA1
MESALAMINE	4	BRCA1
DIPYRIDAMOLE	4	BRCA1
CLOTRIMAZOLE	4	ERBB2
ERLOTINIB HYDROCHLORIDE	4	ERBB2
PONATINIB	4	ERBB2
AFATINIB	4	ERBB2
LAPATINIB DITOSYLATE	4	ERBB2
SORAFENIB	4	ERBB2
NERATINIB	4	ERBB2
IBRUTINIB	4	ERBB2
AFATINIB DIMALEATE	4	ERBB2
CABOZANTINIB	4	ERBB2
DACOMITINIB	4	ERBB2
DACOMITINIB ANHYDROUS	4	ERBB2
VANDETANIB	4	ERBB2
TRIBROMSALAN	4	ERBB2
BOSUTINIB	4	ERBB2
BITHIONOL	4	ERBB2
ASTEMIZOLE	4	ERBB2
EBASTINE	4	ERBB2
OSIMERTINIB	4	ERBB2
BRIGATINIB	4	ERBB2
ACALABRUTINIB	4	ERBB2
ZANUBRUTINIB	4	ERBB2
TUCATINIB	4	ERBB2

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 2.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
ERBB2	1,221	Binding:1136, Functional:79, ADMET:6
BRCA1	13	Binding:9, Functional:4

Cohort enzymes (BRENDA EC)

Symbol	EC numbers	Names
BRCA1	2.3.2.27	RING-type E3 ubiquitin transferase
ERBB2	2.7.10.1	receptor protein-tyrosine kinase

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

Symbol	ChEMBL assays
ERBB2	1,221

Pharmacogenomics

Cohort genes with a PharmGKB record: 3; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Drug repurposing candidates

28 approved/phased drugs hit cohort targets but don’t yet appear in disease-level clinical trials. Target-inhibition rationale is strongest for cancer driver genes; a bioactivity hit is a screening signal, not a treatment claim.

Compound	Max phase	Cohort target (bioactivity)
RIBOFLAVIN	4	BRCA1
DAUNORUBICIN HYDROCHLORIDE	4	BRCA1
TOPOTECAN HYDROCHLORIDE	4	BRCA1
DAUNORUBICIN	4	BRCA1
DOXORUBICIN HYDROCHLORIDE	4	BRCA1
MESALAMINE	4	BRCA1
DIPYRIDAMOLE	4	BRCA1
CLOTRIMAZOLE	4	ERBB2
ERLOTINIB HYDROCHLORIDE	4	ERBB2
PONATINIB	4	ERBB2
AFATINIB	4	ERBB2
LAPATINIB DITOSYLATE	4	ERBB2
NERATINIB	4	ERBB2
IBRUTINIB	4	ERBB2
AFATINIB DIMALEATE	4	ERBB2
DACOMITINIB	4	ERBB2
DACOMITINIB ANHYDROUS	4	ERBB2
VANDETANIB	4	ERBB2
TRIBROMSALAN	4	ERBB2
BOSUTINIB	4	ERBB2
BITHIONOL	4	ERBB2
ASTEMIZOLE	4	ERBB2
EBASTINE	4	ERBB2
OSIMERTINIB	4	ERBB2
BRIGATINIB	4	ERBB2
ACALABRUTINIB	4	ERBB2
ZANUBRUTINIB	4	ERBB2
TUCATINIB	4	ERBB2

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	2	BRCA1, ERBB2
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	1	BRCA2

Undrugged target profiles

1 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
BRCA2	0	BRCA1

Clinical trials & evidence

Clinical trials

Clinical trials: 287.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	109
PHASE1	81
Not specified	41
PHASE1/PHASE2	25
PHASE3	21
EARLY_PHASE1	6
PHASE2/PHASE3	3
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06972693	PHASE4	ACTIVE_NOT_RECRUITING	NGS-based Germline and Somatic Genetic Test in Ovarian Carcinoma
NCT00565851	PHASE3	ACTIVE_NOT_RECRUITING	Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
NCT02446600	PHASE3	ACTIVE_NOT_RECRUITING	Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT02502266	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING	Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer
NCT02839707	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING	Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT02859038	PHASE3	ACTIVE_NOT_RECRUITING	Study of Upfront Surgery Versus Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer (SUNNY)
NCT04498117	PHASE3	ACTIVE_NOT_RECRUITING	Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery
NCT04515602	PHASE3	NOT_YET_RECRUITING	Stratified Evaluation of PDS and NACT-IDS in Ovarian Cancer (FOCUS)
NCT05737303	PHASE3	RECRUITING	Nab-paclitaxel Versus Sb-taxanes As First-Line Treatment in Advanced Ovarian Cancer
NCT06915025	PHASE3	RECRUITING	Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
NCT00011986	PHASE3	COMPLETED	Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer
NCT00047632	PHASE3	TERMINATED	Safety and Efficacy of Interferon Gamma-1b Plus Chemotherapy for Ovarian and Peritoneal Cancer
NCT00954174	PHASE3	UNKNOWN	Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer
NCT01492920	PHASE3	WITHDRAWN	Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy
NCT01506856	PHASE2/PHASE3	COMPLETED	Intraperitoneal Therapy For Ovarian Cancer With Carboplatin Trial
NCT01611766	PHASE3	UNKNOWN	Surgery or Chemotherapy in Recurrent Ovarian Cancer (SOC 1 Trial)?
NCT02328716	PHASE3	UNKNOWN	Cytoreduction With or Without Intraoperative Intraperitoneal Hyperthermic Chemotherapy (HIPEC) in Patients With Peritoneal Carcinomatosis From Ovarian Cancer, Fallopian Tube or Primary Peritoneal Carcinoma
NCT02584478	PHASE3	UNKNOWN	Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)
NCT02631876	PHASE3	COMPLETED	A Study of Mirvetuximab Soravtansine vs. Investigator’s Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer
NCT03180177	PHASE3	UNKNOWN	Efficacy of HIPEC as NACT and Postoperative Chemotherapy in the Treatment of Advanced-Stage Epithelial Ovarian Cancer
NCT03373058	PHASE3	UNKNOWN	Efficacy of HIPEC in the Treatment of Advanced-Stage Epithelial Ovarian Cancer After Cytoreductive Surgery
NCT03905902	PHASE3	WITHDRAWN	DCVAC/OvCa and Standard of Care (SoC) in Relapsed Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma
NCT04201561	PHASE3	UNKNOWN	High Dose Inorganic Selenium for Preventing Chemotherapy Induced Peripheral Neuropathy
NCT04229615	PHASE3	UNKNOWN	A Study of Fluzoparib±Apatinib Versus Placebo Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on First-Line Platinum-Based Chemotherapy
NCT05043402	PHASE3	UNKNOWN	A Study of Navicixizumab in Patients With Platinum Resistant Ovarian Cancer
NCT01012817	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer
NCT02068794	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer
NCT02101775	PHASE2	ACTIVE_NOT_RECRUITING	Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT02124421	PHASE2	ACTIVE_NOT_RECRUITING	HOT: HIPEC in Ovarian Cancer as Initial Treatment
NCT02345265	PHASE2	ACTIVE_NOT_RECRUITING	Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer
NCT02595892	PHASE2	ACTIVE_NOT_RECRUITING	Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT02650986	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1
NCT03029403	PHASE2	ACTIVE_NOT_RECRUITING	Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer
NCT03355976	PHASE2	ACTIVE_NOT_RECRUITING	BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas
NCT03579316	PHASE2	ACTIVE_NOT_RECRUITING	Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT03732950	PHASE2	ACTIVE_NOT_RECRUITING	Pembrolizumab in Treating Participants With Recurrent Ovarian Cancer
NCT03983226	PHASE2	RECRUITING	Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial)
NCT04022213	PHASE2	ACTIVE_NOT_RECRUITING	A Study of the Drug I131-Omburtamab in People With Desmoplastic Small Round Cell Tumors and Other Solid Tumors in the Peritoneum
NCT04034927	PHASE2	ACTIVE_NOT_RECRUITING	Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer
NCT04055649	PHASE2	RECRUITING	ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CARBOPLATIN	4	40
TOPOTECAN	4	13
CABOZANTINIB	4	7
SELUMETINIB	4	6
SORAFENIB	4	6
NIRAPARIB	4	5
OLAPARIB	4	5
MIRVETUXIMAB SORAVTANSINE	4	4
DASATINIB ANHYDROUS	4	3
GEMCITABINE HYDROCHLORIDE	4	3
PAZOPANIB	4	3
TIVOZANIB	4	2
TREMELIMUMAB	4	2
ATEZOLIZUMAB	4	1
AVELUMAB	4	1
BELINOSTAT	4	1
COBIMETINIB	4	1
ENZALUTAMIDE	4	1
IFOSFAMIDE	4	1
INTERFERON GAMMA-1B	4	1
PACLITAXEL	4	1
RAMUCIRUMAB	4	1
RIBOCICLIB	4	1
TEMSIROLIMUS	4	1
TRIENTINE HYDROCHLORIDE	4	1
VELIPARIB	3	14
CEDIRANIB	3	5
OREGOVOMAB	3	3
EPACADOSTAT	3	2
FLUZOPARIB	3	2

Precision-medicine subtype map (CIViC)

Drug × molecular subtype: 2 predictive associations from 2 curated evidence items.

Molecular subtype	Therapy	Effect	Level	CIViC
BRCA1 Mutation OR BRCA2 Mutation	Niraparib	Sensitivity/Response	CIViC A	EID11304
ERBB2 D769Y	Afatinib	Sensitivity/Response	CIViC C	EID11689